Rose Hip and Heart Disease

Helps Prevent Atherosclerotic Plaques

This study features the use of our ABCA1 Antibody. The ATP-binding cassette transporter (ABC) Protein called ABCA1 has a major impact on cellular and whole body cholesterol metabolism and is likely to play an important role in protecting against cardiovascular disease.

The authors conclude that rose hip is a suitable dietary supplement for preventing atherosclerotic plaques formation by modulating systemic blood pressure and the expression of RCT and inflammatory genes.Michele Cavalera, Ulrika Axling, Catarina Rippe, Karl Swärd, and Cecilia Holm. Dietary rose hip exerts anti-atherosclerotic effects and increases nitric oxide-mediated dilation in ApoE-null mice. The Journal of Nutritional Biochemistry. Available online 21 March 2017. http://dx.doi.org/10.1016/j.jnutbio.2017.02.017...Western blotting. Approximately 50 mg of tissue was homogenized in lysis buffer (50 mM Tris–HCl, pH 7.5, 1 mM EGTA, 1 mM EDTA, 1% NP40, 1 mM Na-orthovanadate, 40 mM NaF, 4 mM Na-pyrophosphate, 0.27 M sucrose, 1 mM DTT, 20 μg/ml leupeptin, 10 μg/ml antipain and 1 μg/ml pepstatin) and subsequently centrifuged at 12,000 g for 20 min at 4 °C. Protein concentration of the supernatant was determined using BCA-assay (Pierce) and 20 μg of proteins were resolved on NuPAGE 4–12% Bis-Tris Gel (Life Technologies – Carlsbad, CA) and electroblotted onto nitrocellulose membranes (Amersham, GE Healthcare – UK). The membranes were washed and incubated with primary and appropriate secondary antibodies. Primary antibodies used were: SR-B1 (ab3 - Abcam), beta-actin (A5441 – Sigma), Abca1 (MO13101 - Neuromics), Abcg1 (orb214917, Biorbyt), Abcg5 (orb5656, Biorbyt), Abcg8 (orb228808, Biorbyt), IL1b (orb101745, Biorbyt), IL6 (orb228222, Biorbyt), NF-kB (ab7970, Abcam) and HSP90 (BD610418, BD bioscience)...

RH supplementation modulates the reverse cholesterol transport pathway. (a) Liver qPCR analysis of cholesterol metabolism showed similar expression of genes involved in the synthesis and conversion of cholesterol into bile acids but increased expression of various RCT genes upon rose hip feeding (n=5–6).

(b) Protein levels of SR-B1, Abcg1 and Abcg5 were increased in the liver of RH-feeding mice (n=6). *P<.05, **P<.01 and ^P=.056 versus CTR.

We have an extensive catalog of Characterized, Tested and Research Ready Antibodies/Markers. Check us out.

Chronic Type II Diabetes Mellitus and Cardiovascular Disease

Our Neuropeptide and Neuropeptide Receptors and Leptin and Leptin Receptor Antibdodies are frequently used to study pathologies and biology specific to Obesity and Diabetes.

Here's a new publication studying the relationship between diabetic neuropathy and altered neuropeptide Y and its receptor expression levels in myocardium and plasma.

Robina Matyal, Feroze Mahmood, Michael Robich, Hiliary Glazera, Kamal Khabbaza, Philip Hessa, Cesario Bianchia, Robert Hagberga, Shu-Xu Hua, and Frank W. Sellkea. Chronic type II diabetes mellitus leads to changes in neuropeptide Y receptor expression and distribution in human myocardial tissue. European Journal of Pharmacology. Volume 665, Issues 1-3, 31 August 2011, Pages 19-28.

Abstract: Neuropeptide Y is one of the most abundant neurotransmitters in the myocardium, and is known to influence cardiovascular remodeling. We hypothesized that diabetic neuropathy could possibly be associated with altered neuropeptide Y and its receptor expression levels in myocardium and plasma. Plasma neuropeptide Y levels in diabetic (n = 24, HgbA1c 7.9 ± 1.1%) and non-diabetic (n = 27, HgbA1c 5.8 ± 0.5%) patients undergoing cardiac surgery utilizing cardiopulmonary bypass were analyzed. Right atrial tissue of these patients was used to determine the expression of neuropeptide Y, the receptors 1–5, and leptin by immunoblotting, real-time PCR and immunofluorescence. Apoptosis signaling and endostatin and angiostatin were measured to determine the effects of leptin.


Plasma neuropeptide Y levels were significantly increased in patients with Type II diabetes mellitus as compared to non-diabetic patients (P = 0.026). Atrial tissue neuropeptide Y mRNA levels were lower in diabetic patients (P = 0.036). There was a significant up-regulation of myocardial Y2 and Y5 receptors (P = 0.009, P = 0.01 respectively) in the diabetic patients. Leptin, involved with apoptosis and angiogenesis, was down regulated in diabetic patients (P = 0.05). The levels of caspase-3, endostatin and angiostatin were significantly elevated in diabetic patients (P = 0.003, P = 0.008, P = 0.01 respectively). Y1 receptors were more likely to be localized within the nuclei of cardiomyocytes and vascular smooth muscle cells.


Neuropeptide expression is altered differentially in the serum and myocardium by diabetes. Altered regulation of this system in diabetics may be in part responsible for the decreased angiogenesis, increased apoptosis, and increased vascular smooth muscle proliferation leading to coronary artery disease and heart failure in this patient population.